*LIBTAYO was FDA approved in advanced CSCC in September 2018.1,4
Explore the efficacy of LIBTAYO, including longer-term follow-up data.Explore the data >
Review case studies of patients with advanced CSCC from clinical trials.See the results >
Explore the video library featuring medical experts to learn more about treatment with LIBTAYO.Watch videos >
In an additional cohort in Study 1540 of 56 patients with mCSCC who received LIBTAYO 350 mg Q3W1†:
In this trial, median DOR was not reached (range, 1.9-24.2+ months).1‡
The recommended dosage of LIBTAYO is 350 mg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.1
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way. To view the most recent and complete version of the guidelines, go online to NCCN.org.
References: 1. LIBTAYO (cemiplimab-rwlc) injection full U.S. prescribing information. Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. 2. Study of REGN2810 in patients with advanced cutaneous squamous cell carcinoma. ClinicalTrials.gov website. https://clinicaltrials.gov/ct2/show/study/NCT02760498. Updated January 26, 2021. Accessed April 20, 2021. 3. Rischin D, Khushalani NI, Schmults CD, et al. Phase 2 study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): longer follow-up. Poster presented at: American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program; May 29-31, 2020. 4. Drugs@FDA: FDA-approved drugs. US Food and Drug Administration website. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761097. Updated June 25, 2020. Accessed September 8, 2020. 5. Data on file. Regeneron Pharmaceuticals, Inc. 6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Squamous Cell Skin Cancer V.1.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed March 11, 2021. To view the most recent and complete version of the guidelines, go online to NCCN.org.